Key Takeaways
- West Pharmaceutical’s HVP Components grew 23% organically in Q1 2026, led by GLP-1 demand.
- WST sees Annex 1 upgrades driving premium product adoption and about 200 bps of 2026 growth.
- West Pharmaceutical faces inflation risks and a $40M second-half 2026 SmartDose revenue headwind.
West Pharmaceutical Services, Inc. (WST – Free Report) is well positioned for growth, backed by strong demand for HVPs, expanding GLP-1 drug programs and regulatory-driven Annex 1 conversions. However, tariff impacts, destocking in generics and execution challenges at constrained European facilities are concerning.
Shares of this Zacks Rank #1 (Strong Buy) company have gained 11% year to date compared to the industry‘s 9.3% decline. The S&P 500 Index has risen 8.1% in the same time frame.
West Pharmaceutical, with a market capitalization of $21.47 billion, is a leading global manufacturer, engaged in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable drugs and healthcare products. Its earnings are anticipated to improve 13.9% over the next five years. The company delivered a trailing four-quarter average earnings surprise of 19.37%.
Image Source: Zacks Investment Research
Positive Factors Driving WST’s Prospects
HVP Components Growth Reinforcing a Premium Business Mix: West Pharma’s strongest growth driver remains its HVP Components business, which grew 23% organically in the first quarter of 2026, supported by robust demand across GLP-1 and non-GLP-1 applications.
The non-GLP-1 HVP growth accelerated into the high teens, driven by biologics, biosimilars and premiumization through Annex 1 upgrades. The segment’s strength reflects not just cyclical demand, but a structural shift toward premium injectable containment solutions, where West commands higher pricing and margins.
Management also highlighted that over two-thirds of HVP outperformance came from non-GLP-1 products, reducing investor concerns around concentration risk in obesity therapies and reinforcing a more durable long-term growth outlook.
Annex 1 Regulations Creating a Multi-Year Premiumization Tailwind: West Pharma continues to benefit from regulatory tightening around injectable drug sterility, particularly under EU Annex 1 standards, which are driving pharmaceutical customers to upgrade from standard elastomer products to higher-value HVP offerings.
Management expects Annex 1 and HVP conversion to contribute approximately 200 basis points of annual growth in 2026, with momentum accelerating as projects increase 66% year over year. Adoption is beginning to spread beyond Europe into the United States and Asia as manufacturers standardize sterility requirements globally.
Since these upgrades improve average selling prices and margins without requiring major volume increases, Annex 1 represents a high-quality, long-duration growth lever capable of structurally enhancing profitability.
GLP-1 Exposure Remains a Powerful and Expanding Demand Driver: West Pharma’s GLP-1 franchise continues to outperform, with GLP-1-related HVP revenues accounting for 10% of total company sales, supported by strong injectable demand and expanding therapeutic adoption.
Management remains confident that oral GLP-1s are complementing rather than cannibalizing the injectable market, supporting sustained elastomer demand. Additional growth drivers include broader insurance coverage, lower drug pricing, FDA decisions on compounded GLP-1s, new indications beyond diabetes and obesity, and international generic launches. This diversified demand base reduces reliance on a single product cycle and positions West Pharma as a key enabler of one of healthcare’s largest long-term therapeutic opportunities.
Operational Excellence and Capacity Unlock Improving Margins: West Pharma’s operational execution emerged as a significant differentiator in the first quarter, helping adjusted operating margins expand 350 basis points to 21.4%.
Rather than relying solely on new factory buildouts, management is increasing output through process optimization, accelerated onboarding and the transfer of best practices across manufacturing sites.
The company highlighted meaningful productivity gains in Europe that are now being replicated across facilities in the United States, enabling faster scaling of HVP demand with lower incremental capital intensity. This operational leverage not only supports near-term revenue growth but also creates additional upside for margin expansion as fixed manufacturing costs are absorbed more efficiently over time.
Key Challenges Facing WST
Commodity, Fuel and Oil Inflation Could Pressure Margins: West Pharma acknowledged growing cost pressures related to oil, logistics and commodity inflation, particularly following geopolitical disruptions in the Middle East.
While management expects only a single-digit million net impact after mitigation efforts, inflationary pressures remain a meaningful operational risk due to the petroleum-linked nature of elastomer manufacturing and logistics.
Although hedging, pricing actions and operational efficiencies provide partial offsets, sustained energy volatility could compress gross margins if costs rise faster than customer pass-through mechanisms. Given the company’s premium margin profile, even modest inflationary pressure can influence earnings expectations.
SmartDose Divestiture Creates a Second-Half Revenue Headwind: West Pharma continues to expect the midyear divestiture of SmartDose, which creates a notable second-half comparison challenge. Management highlighted an expected $40 million revenue headwind in the back half of 2026 due to the contract roll-off, contributing to a more front-half-weighted revenue profile.
Although the company expects stronger contributions from drug handling and other delivery device businesses over time, there is a timing mismatch between the SmartDose exit and replacement growth. This transition could create temporary volatility in growth rates and operating leverage during the second half of the year.
Estimate Trend
WST has been witnessing a positive estimate revision for 2026. In the past 30 days, the Zacks Consensus Estimate for earnings has moved north 8.7% to $8.60 per share, implying a gain of 18% from the prior-year reported level. The consensus mark for revenues is pegged at $3.32 billion, indicating an 8% increase from the 2025 reported level.
Other Key Picks
Some other top-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB – Free Report) , Globus Medical (GMED – Free Report) and Biodesix (BDSX – Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB’s earnings are estimated to decline 12.2% in 2027, against the industry’s projected growth of 16.9%. The company has beaten earnings estimates in each of the trailing four quarters, with an average surprise of 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.